Tonix Pharmaceuticals Holding (TNXP) Operating Leases (2019 - 2026)

Tonix Pharmaceuticals Holding's Operating Leases history runs 8 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• On a quarterly basis, Operating Leases rose 129.13% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $1.3 million, a 129.13% increase from a year earlier, with the FY2025 full-year figure at $1.2 million, up 230.73% from the prior year.
• Operating Leases improved to $1.3 million in Q1 2026 per TNXP's latest filing, from $1.2 million in the prior quarter.
• Across five years, Operating Leases topped out at $1.3 million in Q1 2026 and bottomed at $297000.0 in Q2 2025.
• The 5-year median for Operating Leases is $563000.0 (2024), against an average of $628176.5.
• Across the five-year window, Operating Leases tumbled 45.1% in 2024 and surged 230.73% in 2025, its largest moves.
• Year by year, Operating Leases stood at $328000.0 in 2022, then surged by 92.68% to $632000.0 in 2023, then sank by 43.35% to $358000.0 in 2024, then jumped by 230.73% to $1.2 million in 2025, then climbed by 8.95% to $1.3 million in 2026.
• Per Business Quant, the three latest TNXP Operating Leases figures stand at $1.3 million (Q1 2026), $1.2 million (Q4 2025), and $425000.0 (Q3 2025).